What the evidence shows
- A double-blind trial compared lion’s mane with a dummy pill in 30 Japanese adults with mild cognitive impairment.
- The trial reported higher cognitive scores at weeks 8, 12, and 16, followed by a significant fall after use ended.
- A 10-person pilot in healthy adults reported no statistically significant changes in executive function or plasma BDNF.
- A cell study reported changes in a human neuroblastoma cell line; it was not a clinical trial in adults.
A placebo-controlled trial studied adults with mild cognitive impairment
One trial studied Japanese men and women aged 50 to 80 with mild cognitive impairment. It used a double-blind, parallel-group design and compared lion’s mane with a dummy pill. After two weeks of preliminary examination, researchers assigned 30 people to two groups of 15. The study measured cognitive function with a scale based on the Revised Hasegawa Dementia Scale. Participants took the assigned mushroom or dummy pill for 16 weeks, then researchers observed them for four more weeks.
The trial reported higher scores during mushroom use
At weeks 8, 12, and 16, the lion’s mane group had significantly higher cognitive-function scores than the dummy-pill group. Scores in the lion’s mane group rose with longer use. Four weeks after use ended, those scores fell significantly. Laboratory tests showed no adverse effect from lion’s mane. The authors said their results suggested that lion’s mane improved mild cognitive impairment. These findings describe the 30 participants and the measures used in this trial.
A small pilot studied healthy adults
A separate pilot studied 10 healthy adults aged 18 to 55. They used a lion’s mane supplement for four weeks. Researchers measured executive function with two NIH Toolbox tests and measured plasma BDNF. The study reported no statistically significant changes in executive function or BDNF. It reported small-to-moderate effect sizes: 0.48 for the Flanker test, 0.25 for the card sort test, and 0.31 for BDNF. The authors described the supplement as safe and well tolerated in this study.
Cell findings are not trial findings in people
A study of a lion’s mane extract blend examined SH-SY5Y cells, a human neuroblastoma cell line. The treated cells showed neuron-like differentiation and greater neuronal excitability. The study also reported higher levels of neuronal markers, including βIII-tubulin and synaptotagmin. PCNA and stemness markers fell. These are findings in cells, not results from a clinical trial in adults with mild cognitive impairment. The abstract describes potential implications for neuroblastoma and other neurological disorders.
What these studies reported
The placebo-controlled trial reported higher cognitive-function scores during lion’s mane use among adults with mild cognitive impairment. It also reported that scores fell after use ended. The healthy-adult pilot reported no statistically significant changes in its measured outcomes. The cell study reported changes in a human cell line. Together, these abstracts describe different populations, methods, and outcomes. They do not report the same kind of study or measure.
Sources
- Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy research : PTR, 2009.
- A Pilot Proof-of-Concept Study to Evaluate the Physiological and Cognitive Impacts of Hericium erinaceus on Healthy Adults. Nutrients, 2026.
- Hericium erinaceus extracts promote neuronal differentiation and excitability through nootropic metabolite activity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025.
About this article
NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.
